Home > Protocol Summaries: Compounds > GSK2251052 Protocol Summaries: GSK2251052 GSKStudy ID Phase Title Status 114470 phase 1 A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects Completed 114688 phase 2 A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with febrile complicated lower urinary tract infections and acute pyelonephritis Terminated 114689 phase 2 A prospective, randomized, double-blind, multi-center, dose-ranging study of the safety, tolerability and efficacy of GSK2251052 in the treatment of complicated intra-abdominal infections in adults Terminated 114926 phase 1 An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects Completed 115243 phase 1 An Open Label, Non-Randomized, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2251052 Administered as a Single Intravenous Dose to Healthy Adult Subjects Completed 115244 phase 1 A study to evaluate the relative bioavailability of five different oral formulations of GSK2251052 and the multiple-dose, safety, tolerability, and pharmacokinetics of GSK2251052 with and without food in male and female, young and elderly healthy volunteers Terminated 116160 phase 1 A two part study to evaluate the safety, tolerability, and pharmacokinetics of GSK2251052 after single ascending dosesand repeat doses of IV GSK2251052 in healthy male Japanese and Caucasian subjects and a repeat dose study to evaluatesupratherapeutic doses of IV GSK2251052 in healthy volunteers Terminated
